CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
OPERATING ACTIVITIES:
Net loss	$ (184,023,000)	$ (75,121,000)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Stock-based compensation expense	100,323,000	47,967,000
Depreciation	21,414,000	20,471,000
Amortization of purchased intangibles and finance leases	16,530,000	4,939,000
Amortization of debt issuance costs	2,831,000	1,858,000
Accretion of debt discount on convertible senior notes	0	24,770,000
Allowance for credit losses	4,669,000	2,431,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	(8,568,000)	0
Gain on settlement of leases	0	(3,483,000)
Deferred income taxes	770,000	(1,129,000)
Changes in operating assets and liabilities:
Accounts receivable	(13,856,000)	(5,827,000)
Prepaid expenses and other current assets	(13,519,000)	(10,269,000)
Contract acquisition costs noncurrent	(2,842,000)	(4,765,000)
Other assets	(123,000)	741,000
Accounts payable	(4,229,000)	(354,000)
Accrued expenses and other current liabilities	(12,234,000)	22,176,000
Deferred revenue	7,450,000	14,925,000
Operating lease liabilities	(2,148,000)	(4,018,000)
Other liabilities	8,084,000	330,000
Net cash (used in) provided by operating activities	(79,471,000)	35,642,000
INVESTING ACTIVITIES:
Purchases of property and equipment, including capitalized software	(35,212,000)	(33,821,000)
Investment in joint venture	(3,993,000)	0
Payments for acquisition, net of cash acquired	(3,458,000)	(23,014,000)
Repayment of debt acquired in acquisition	0	(1,955,000)
Payments for intangible assets	(1,394,000)	(1,931,000)
Net cash used in investing activities	(44,057,000)	(60,721,000)
FINANCING ACTIVITIES:
Principal payments for financing leases	(2,785,000)	(2,604,000)
Proceeds from issuance of common stock in connection with the exercise of options and ESPP	1,238,000	13,127,000
Payments on conversion of convertible senior notes	0	(2,000)
Net cash (used in) provided by financing activities	(1,547,000)	10,521,000
Effect of foreign exchange rate changes on cash and cash equivalents	(4,713,000)	(5,072,000)
Net decrease in cash, cash equivalents, and restricted cash	(129,788,000)	(19,630,000)
Cash, cash equivalents, and restricted cash - beginning of year	523,532,000	654,152,000
Cash, cash equivalents, and restricted cash - end of period	393,744,000	634,522,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	393,330,000	633,042,000
Restricted cash in prepaid expenses and other current assets	414,000	1,480,000
Total cash, cash equivalents, and restricted cash	393,744,000	634,522,000
Supplemental disclosure of other cash flow information:
Cash paid for income taxes	3,079,000	2,219,000
Cash paid for interest	1,895,000	1,981,000
Supplemental disclosure of non-cash investing and financing activities:
Increase in convertible senior notes, net upon adoption of ASU 2020-06 (Note 1)	159,407,000	0
Purchase of property and equipment recorded in accounts payable	113,000	581,000
Issuance of shares of common stock to settle cash awards	17,298,000	33,503,000
Right of use assets obtained in exchange for operating lease liabilities	2,417,000	1,856,000
Noncash or part noncash acquisition, contingent liability	6,113,000
Noncash or part noncash acquisition, contingent liability	6,113,000
WildHealth
Supplemental disclosure of non-cash investing and financing activities:
Stock issued	$ 17,675,000	0
Issuance of 779,946 shares of common stock in connection with the WildHealth transaction in February 2022 (shares)	776,825
Noncash or part noncash acquisition, contingent liability	$ 38,151,000	0
Issuance of 779,946 shares of common stock in connection with the WildHealth transaction in February 2022 (shares)	776,825
Stock issued	$ 17,675,000	0
Noncash or part noncash acquisition, contingent liability	38,151,000	0
ebot-7
Supplemental disclosure of non-cash investing and financing activities:
Stock issued	$ 0	20,012,000
Issuance of 779,946 shares of common stock in connection with the WildHealth transaction in February 2022 (shares)	351,462
Issuance of 779,946 shares of common stock in connection with the WildHealth transaction in February 2022 (shares)	351,462
Stock issued	$ 0	20,012,000
ebot-7 | Contingent earn-out
Supplemental disclosure of non-cash investing and financing activities:
Noncash or part noncash acquisition, contingent liability		6,026,000
Noncash or part noncash acquisition, contingent liability		$ 6,026,000